Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations

Research output: Contribution to journalReviewResearchpeer-review

  1. Airway gene expression identifies subtypes of type 2 inflammation in severe asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Real-world evidence: Methods for assessing long-term health and effectiveness of allergy immunotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The mannitol test is an indirect bronchial challenge test widely used in diagnosing asthma. Response to the mannitol test correlates with the level of eosinophilic and mast cell airway inflammation, and a positive mannitol test is highly predictive of a response to anti-inflammatory treatment with inhaled corticosteroids. The response to mannitol is a physiological biomarker that may, therefore, be used to assess the response to other anti-inflammatory treatments and may be of particular interest in early phase studies that require surrogate markers to predict a clinical response. The main objectives of this review were to assess the practical aspects of using mannitol as an endpoint in clinical trials and provide the clinical researcher and respiratory physician with recommendations when designing early clinical trials.

METHODS: The aim of this review was to summarise previous uses of the mannitol test as an outcome measure in clinical intervention studies. The PubMed database was searched using a combination of MeSH and keywords. Eligible studies included intervention or repeatability studies using the standard mannitol test, at multiple timepoints, reporting the use of PD15 as a measure, and published in English.

RESULTS: Of the 193 papers identified, 12 studies met the inclusion criteria and data from these are discussed in detail. Data on the mode of action, correlation with airway inflammation, its diagnostic properties, and repeatability have been summarised, and suggestions for the reporting of test results provided. Worked examples of power calculations for dimensioning study populations are presented for different types of study designs. Finally, interpretation and reporting of the change in the response to the mannitol test are discussed.

CONCLUSIONS: The mechanistic and practical features of the mannitol test make it a useful marker of disease, not only in clinical diagnoses, but also as an outcome measure in intervention trials. Measuring airway hyperresponsiveness to mannitol provides a novel and reproducible test for assessing efficacy in intervention trials, and importantly, utilises a test that links directly to underlying drivers of disease.

Original languageEnglish
Article number287
JournalRespiratory Research
Volume22
Issue number1
Pages (from-to)287
ISSN1465-9921
DOIs
Publication statusPublished - 7 Nov 2021

Bibliographical note

© 2021. The Author(s).

ID: 69006500